Abstract

The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm with variable glucose setpoints and moderate intensity exercise using an investigational device in adults with type 1 diabetes (T1D).A supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient standard treatment phase. Adults aged 18-65 years with T1D and HbA1c between 6.0% and 10.0% were eligible. Subjects completed two moderate intensity exercise sessions of >30?min duration on consecutive days: the first with the glucose set point increased from 130 to 150?mg/dL and the second with a temporary basal rate of 50%, both started 90?min pre-exercise. Primary endpoints were percentage time in hypoglycemia <70?mg/dL and hyperglycemia =250?mg/dL.Twelve subjects participated in the study, with (mean?±?standard deviation) age 36.5?±?14.4 years, diabetes duration 21.7?±?15.7 years, HbA1c 7.6%?±?1.1%, and total daily dose 0.60?±?0.22?U/kg. Outcomes for the 54-h HCL period were mean glucose: 136?±?14?mg/dL, percentage time <70?mg/dL: 1.4%?±?1.3%, 70-180?mg/dL: 85.1%?±?9.3%, and =250?mg/dL: 1.8%?±?2.4%. In the 12-h period after exercise start, percentage time <70?mg/dL was 1.4%?±?2.7% with the raised glucose set point and 1.6%?±?3.0% with reduced basal rate. The percentage time <70?mg/dL overnight was 0%?±?0% on both study nights.The Omnipod personalized MPC algorithm performed well and was safe during day and night use in response to variable glucose set points and with temporarily raised glucose set point or reduced basal rate 90?min in advance of moderate intensity exercise in adults with T1D.

View details for DOI 10.1089/dia.2019.0017

View details for PubMedID 30925077